Zilbrysq (Zilucoplan Sodium) Patent Expiration, LOE Window & CMS Spending
Zilbrysq (Zilucoplan Sodium) by Ucb: FDA Orange Book core substance LOE 2035-06-12, 0 AB generics, $40.8M 2024 CMS Part D & Medicaid spend, and $41,300 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ucb |
| FDA Application & Pathway | N216834 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2035-06-12 |
| Last Listed Patent or Exclusivity Date | 2035-06-12 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $40.8M |
| 2024 Medicare Part D Spend | $37.1M |
| 2024 Medicaid Spend | $3.6M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($41,300 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.